Brainstorm Cell Therapeutics Inc., of Hackensack, N.J., said it signed definitive agreements with Massachusetts General Hospital and California Pacific Medical Center to enroll patients in the planned phase III trial of stem cell therapy candidate Nurown in amyotrophic lateral sclerosis, pending FDA and institutional review board approvals.